The main goals were to compare the efficacy of extracts of the plant Tribulus terrestris (TT; marketed as Tribestan), in comparison with placebo, for the treatment of men with erectile dysfunction (ED) and with or without hypoactive sexual desire disorder (HSDD), as well as to keep an eye on the security profile of the drug.
Phase IV, prospective, randomized, double-blind, placebo-controlled clinical trial in parallel groups. This study consisted of 180 males aged in between 18 and 65 years with mild or moderate ED and with or without HSDD: 90 were randomized to TT and 90 to placebo. tribestan 250mg with ED and high blood pressure, diabetes mellitus, and metabolic syndrome were included in the study.
Each Tribestan film-coated tablet contains the active compound Tribulus terrestris, herba extractum siccum (35-45:1) 250mg which is standardized to furostanol saponins (not less than 112. 5mg). Each patient got orally 32 film-coated tablets daily after meals, during the 12-week treatment duration. At the end of monthly, individuals' sexual function, consisting of ED, was evaluated by International Index of Erectile Function (IIEF) Questionnaire and Worldwide Efficacy Concern (GEQ).
The main outcome procedure was the change in IIEF score after 12 weeks of treatment. Total randomization (random sorting using maximum allowed% discrepancy) with an equivalent variety of clients in each series was used. This randomization algorithm has the restriction that unequal treatment allocation is not allowed; that is, all groups need to have the very same target sample size.
All outcome assessors were likewise blinded to group allotment. 86 patients in each group completed the study. The IIEF score improved considerably in the TT group compared to the placebo group (